Results for this period
Third quarter1 October 2025 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The company received an initial milestone achievement payment and joint research expenses under its joint research with Ono Pharmaceutical Co., Ltd., as well as a milestone achievement payment from an undisclosed partner company. On the other hand, selling, general and administrative expenses increased due to higher research and development expenses.
A description of significant events and conditions is provided. Although events or conditions exist that raise substantial doubt about the going-concern assumption due to continuing operating losses and negative operating cash flow, the company has secured funding for its business activities at least for the foreseeable future and believes that no material uncertainty exists. No note regarding the going-concern assumption is applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 October 2025 to 30 June 2026 |
| Net Sales | ¥369 million (YoY +19.4%) |
| Operating profit | ¥-829 million |
| Ordinary income | ¥-800 million |
| Profit attributable to owners of the parent | ¥-845 million |
| Net income per share | △22.90 |
| Equity ratio | End of the current fiscal period 75.7 / End of previous period 87.6 |
| Total assets | ¥2,474 million |
| Net assets | ¥1,890 million |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Reason Because it is not currently possible to calculate a reasonable earnings forecast |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Impairment loss | ¥43,264 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥99 thousand, Impairment Losses ¥43,264 thousand |
| Disclosure regarding the going concern assumption | A description of significant events and conditions is provided. Although events or conditions exist that raise substantial doubt about the going-concern assumption due to continuing operating losses and negative operating cash flow, the company has secured funding for its business activities at least for the foreseeable future and believes that no material uncertainty exists. No note regarding the going-concern assumption is applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 36,964,000 Shares |
| Factors Behind Changes in Business Performance | The company received an initial milestone achievement payment and joint research expenses under its joint research with Ono Pharmaceutical Co., Ltd., as well as a milestone achievement payment from an undisclosed partner company. On the other hand, selling, general and administrative expenses increased due to higher research and development expenses. |
Items this document does not state (16)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company received an initial milestone achievement payment and joint research expenses under its joint research with Ono Pharmaceutical Co., Ltd., as well as a milestone achievement payment from an undisclosed partner company. Selling, general and administrative expenses increased due to higher research and development expenses, resulting in a wider operating loss.